How we approach the perioperative management of patients with chronic lymphocytic leukaemia receiving continuous cancer-directed therapies
© 2023 British Society for Haematology and John Wiley & Sons Ltd..
Historically, invasive procedures and surgeries were deferred in patients with haematological malignancies including advanced stage chronic lymphocytic leukaemia (CLL) because of limited life expectancy. However, novel, and often continuous, treatments have markedly improved outcomes in CLL. Some patients may expect years of treatment response and disease control, overcoming the short life expectancy that deters interventionalists. Such patients now often undergo various invasive procedures including major surgery. To inform peri-operative management, we summarize the relevant side effects and drug interactions of continuous CLL therapies, highlight potential surgical risks, and provide recommendations on withholding specific CLL drugs around invasive procedures.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:201 |
|---|---|
| Enthalten in: |
British journal of haematology - 201(2023), 2 vom: 21. Apr., Seite 215-221 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Helen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 06.04.2023 Date Revised 07.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.18661 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351930736 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351930736 | ||
| 003 | DE-627 | ||
| 005 | 20231226052554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.18661 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM351930736 | ||
| 035 | |a (NLM)36682358 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Helen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How we approach the perioperative management of patients with chronic lymphocytic leukaemia receiving continuous cancer-directed therapies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.04.2023 | ||
| 500 | |a Date Revised 07.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Historically, invasive procedures and surgeries were deferred in patients with haematological malignancies including advanced stage chronic lymphocytic leukaemia (CLL) because of limited life expectancy. However, novel, and often continuous, treatments have markedly improved outcomes in CLL. Some patients may expect years of treatment response and disease control, overcoming the short life expectancy that deters interventionalists. Such patients now often undergo various invasive procedures including major surgery. To inform peri-operative management, we summarize the relevant side effects and drug interactions of continuous CLL therapies, highlight potential surgical risks, and provide recommendations on withholding specific CLL drugs around invasive procedures | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CLL | |
| 650 | 4 | |a cardio-oncology | |
| 650 | 4 | |a chronic lymphocytic leukaemia | |
| 650 | 4 | |a surgical procedures | |
| 650 | 4 | |a therapeutics | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Wang, Stephani |e verfasserin |4 aut | |
| 700 | 1 | |a O'Brien, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Kern, Morton |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Pankaj |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 201(2023), 2 vom: 21. Apr., Seite 215-221 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:201 |g year:2023 |g number:2 |g day:21 |g month:04 |g pages:215-221 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.18661 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 201 |j 2023 |e 2 |b 21 |c 04 |h 215-221 | ||